AstraZeneca PLC (AZN) vs Biogen Inc. (BIIB)
- AstraZeneca PLC AZN 165.41 −0.76%
- Biogen Inc. BIIB 232.65 −1.15%
AstraZeneca PLC and Biogen Inc. are both Drug Manufacturers General companies. AstraZeneca PLC is the larger, with a market value of $258.5B against $34.8B — 7.4× the size. AstraZeneca PLC trades at the lower P/E: 24.5× against 41.0×. AstraZeneca PLC grew revenue faster over the last twelve months: 8.61% against 0.31%. AstraZeneca PLC has the higher net margin (17.0% vs 8.32%) and the higher return on invested capital (11.7% vs 3.11%). Across the 22 metrics below, AstraZeneca PLC leads on 13 and Biogen Inc. on 9.
Valuation
Profitability
| Metric | AZN | BIIB | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 81.88% | 73.99% | 72.77% |
| Operating margin | 22.77% | 12.35% | 18.77% |
| Net margin | 17.02% | 8.32% | 8.27% |
| Free cash flow margin | 10.21% | 25.33% | 17.18% |
| Return on equity | 21.95% | 4.58% | 5.87% |
| Return on assets | 9.15% | 2.76% | 2.57% |
| Return on invested capital | 11.67% | 3.11% | 6.11% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack